TY - JOUR
T1 - Acute oral administration of lauric acid reduces energy intake in healthy male
AU - Feltrin, K. L.
AU - Brennan, I.M.
AU - Rades, Thomas
AU - Horowitz, M.
AU - Feinle-Bisset, C.
PY - 2014
Y1 - 2014
N2 - Background and aims: We have established that acute intraduodenal infusion of the fatty acid, lauric acid ("C12"), markedly reduces energy intake in healthy subjects in the absence of adverse effects. The aim of this study was to investigate the hypothesis that increasing doses of orally ingested C12 would result in a dose-related suppression of appetite and subsequent energy intake at breakfast and lunch. Methods: 14 healthy men were studied on four separate occasions in double-blind, randomised fashion. Following ingestion of C12 (2g (77kJ), 4g (153kJ), or 6g (230kJ)) or control, energy intake at breakfast (30min after C12 ingestion), perceptions of appetite, nausea and bloating (for 180min following breakfast), and energy intake at lunch (180min after breakfast), were measured. Results: C12 ingestion did not induce nausea or bloating. While there was no effect of C12 on energy intake at breakfast, energy intake at lunch was reduced significantly after ingestion of both C12(2g) (by 13.7%, P<0.05) and C12(6g) (by 18.1%, P<0.01) compared with control, and tended to be less (by 8.7%, P=0.1) following C12(4g) (kJ; control: 4232±151, C12(2g): 3667±283, C12(4g): 3874±315, C12(6g): 3474±237). Total energy intake (breakfast+lunch+C12 dose) was less following ingestion of C12(6g) compared with control (by 7.8%, P<0.05) (kJ; control: 8256±297, C12(2g): 7905±269, C12(4g): 8443±421, C12(6g): 7611±384). Conclusion: Acute administration of oral C12 reduces energy intake in lean humans. Clinical trial registration: This study was performed in 2006/2007, i.e. prior to the requirement of clinical trial registration and, therefore, was not registered at the time.
AB - Background and aims: We have established that acute intraduodenal infusion of the fatty acid, lauric acid ("C12"), markedly reduces energy intake in healthy subjects in the absence of adverse effects. The aim of this study was to investigate the hypothesis that increasing doses of orally ingested C12 would result in a dose-related suppression of appetite and subsequent energy intake at breakfast and lunch. Methods: 14 healthy men were studied on four separate occasions in double-blind, randomised fashion. Following ingestion of C12 (2g (77kJ), 4g (153kJ), or 6g (230kJ)) or control, energy intake at breakfast (30min after C12 ingestion), perceptions of appetite, nausea and bloating (for 180min following breakfast), and energy intake at lunch (180min after breakfast), were measured. Results: C12 ingestion did not induce nausea or bloating. While there was no effect of C12 on energy intake at breakfast, energy intake at lunch was reduced significantly after ingestion of both C12(2g) (by 13.7%, P<0.05) and C12(6g) (by 18.1%, P<0.01) compared with control, and tended to be less (by 8.7%, P=0.1) following C12(4g) (kJ; control: 4232±151, C12(2g): 3667±283, C12(4g): 3874±315, C12(6g): 3474±237). Total energy intake (breakfast+lunch+C12 dose) was less following ingestion of C12(6g) compared with control (by 7.8%, P<0.05) (kJ; control: 8256±297, C12(2g): 7905±269, C12(4g): 8443±421, C12(6g): 7611±384). Conclusion: Acute administration of oral C12 reduces energy intake in lean humans. Clinical trial registration: This study was performed in 2006/2007, i.e. prior to the requirement of clinical trial registration and, therefore, was not registered at the time.
U2 - 10.1016/j.clnme.2014.01.004
DO - 10.1016/j.clnme.2014.01.004
M3 - Journal article
SN - 2405-4577
VL - 9
SP - 69
EP - 75
JO - Clinical Nutrition ESPEN
JF - Clinical Nutrition ESPEN
IS - 2
ER -